HLA-C and neoplasm: Briefly, mutations are called by whole-exome or whole-genome sequencing of tumor vs. germline DNA, are further filtered by in silico prediction algorithms and potentially tumor RNA sequencing immunopeptidomics, primarily taking into account peptide-MHC binding affinity and RNA expression as well as direct identification (15).